Stratum Nutrition's OraCMU Gains Health Canada Approval

Stratum Nutrition’s OraCMU, an oral probiotic ingredient developed by Oraticx, has received a Health Canada product license, authorizing its sale and distribution in Canada's natural health products market.¹

The license, granted under Natural Product Number 80149686, permits OraCMU powder to be marketed as supporting oral health, promoting a healthy oral microbiota, and helping reduce halitosis by supporting that microbiota. For manufacturers formulating oral care or microbiome-focused supplements, the approval extends an ingredient's regulatory footprint into a second major North American market.

"Health Canada's approval marks a significant milestone for OraCMU and creates exciting new opportunities for our partners to bring innovative oral health solutions to Canadian consumers," said Arun Nair, PhD, Stratum Nutrition’s chief commercial officer. "As consumer interest in microbiome-focused wellness continues to accelerate, OraCMU provides brands with a clinically studied ingredient that promotes oral health by helping maintain a balanced oral microbiome."¹

What Human Clinical Evidence Supports OraCMU for Halitosis?

OraCMU is built around Weissella cibaria CMU, a bacterial strain isolated for its ability to inhibit oral pathogens that produce volatile sulfur compounds, the primary chemical cause of bad breath.

In a randomized, double-blind, placebo-controlled trial of 100 adults with halitosis, participants who took a daily tablet containing the strain for 8 weeks showed improvements in subjective bad-breath scores and psychological indicators tied to oral health-related quality of life, compared with placebo.²

A more recent randomized, double-blind, placebo-controlled trial extended this research to 80 adults with gingivitis and early-stage periodontitis, finding that 8 weeks of OraCMU supplementation improved halitosis measures and reduced levels of certain periodontal pathogens compared with placebo.³

How Does Oral Probiotic Research Fit Into Current Halitosis Management?

Halitosis is most commonly addressed through mechanical approaches, brushing, flossing, tongue cleaning, and antimicrobial mouth rinses, aimed at reducing the anaerobic bacteria responsible for producing volatile sulfur compounds in the mouth. Oral probiotics represent a comparatively newer strategy, working by competing with odor-producing bacteria for space and resources in the oral cavity rather than directly killing them. Unlike probiotic strains developed for digestive health, Weissella cibaria CMU was isolated and studied specifically for its activity within the oral cavity, giving it a more direct evidence base for this particular application than probiotics adapted from gut-health formulations.

What Are the Remaining Questions About OraCMU in the Canadian Market?

Health Canada's approval reflects a determination that the ingredient's safety and supporting evidence meet the threshold required for a natural health product license under the specific claims listed, not an independent efficacy review comparable to a drug approval. Longer-term studies, larger sample sizes, and research in broader consumer populations, rather than clinical patients with existing periodontal disease, would help clarify how consistently the strain performs outside the trial settings published to date.

References

1. Stratum Nutrition. Stratum Nutrition expands OraCMU into Canadian market following Health Canada approval. July 24, 2026. Accessed July 29. 2026. https://stratumnutrition.com/human/posts/detail/stratum-nutrition-expands-ora-cmu-into-canadian-market-following-health-canada-approval

2. Han HS, Yum H, Cho YD, Kim S. Improvement of halitosis by probiotic bacterium Weissella cibaria CMU: a randomized controlled trial. Front Microbiol. 2023;14:1108762. doi:10.3389/fmicb.2023.1108762

3. Lee SK, Lim KO, Yang KI, You SJ, Kang MS, Lee WP. Oral probiotic Weissella cibaria improves halitosis and reduces periodontal pathogens: a randomized, double-blind, placebo-controlled trial. BMC Oral Health. 2026. doi:10.1186/s12903-026-08003-4